No Data
Market Cool On GemPharmatech Co., Ltd.'s (SHSE:688046) Earnings
Yakkang Biotech: Yakang Biotech Report for the Third Quarter of 2024
Yakkang Biotech Report for the Third Quarter of 2024
Yao Kang Biology (688046.SH): Achieved net income of 98.2144 million yuan in the first three quarters.
Pharmaron (688046.SH) announced on October 30th that the company achieved revenue of 0.51 billion yuan in the first three quarters of 2024, a year-on-year increase of 12.13%; the net income attributable to the shareholders of the listed company was 98.2144 million yuan, a year-on-year decrease of 16.57%, with a basic earnings per share of 0.24 yuan.
Shareholder Qingdao Guoyao of Yaokang Biological (688046.SH) reduced its shareholding by 0.8882 million shares, decreasing its stake to 5%.
Yao Kang Biology (688046.SH) announced that on September 24, 2024, the shareholder Qingdao National Pharmaceutical Daichuang ...
We Think That There Are More Issues For GemPharmatech (SHSE:688046) Than Just Sluggish Earnings
Investor Optimism Abounds GemPharmatech Co., Ltd. (SHSE:688046) But Growth Is Lacking
No Data
